Antibody-Based Conjugation

Antibody-delivery system conjugation is a powerful strategy in modern medicine that combines the unparalleled specificity of antibodies with the versatile properties of delivery systems like nanoparticles and liposomes. The antibody acts as a homing beacon, recognizing and binding to specific biomarkers or antigens on the surface of target cells (e.g., cancer cells). The delivery system, in turn, protects the payload from degradation, improves its solubility, and controls its release at the target site. This conjugation strategy is critical for overcoming the limitations of traditional therapies by reducing systemic toxicity and enhancing therapeutic efficacy.

The success of antibody-based delivery systems hinges on the choice of conjugation chemistry. The goal is to attach the antibody to the delivery system in a way that preserves the antibody's binding affinity while maintaining the stability and functionality of the overall conjugate. We specialize in various conjugation methods:

• Antibody-LNP Conjugation (Ab-LNP): Lipid Nanoparticles (LNPs) are an effective platform for delivering nucleic acids like mRNA, but they often lack cell-specific targeting. Antibody-LNP Conjugation addresses this by linking a monoclonal antibody (mAb) to the LNP surface. This creates a "smart" system that uses the antibody as a homing beacon to deliver the therapeutic payload directly to target cells, combining the LNP's delivery power with the antibody's precise targeting. This approach is promising for applications like targeted RNA therapy for cancer and inflammatory diseases.

Fig.2 Targeted delivery via antibody-conjugated NPs.^2,4

• Immunoliposomes: This involves attaching an antibody to the surface of a liposome, a spherical vesicle made of lipid bilayers. Immunoliposomes are a well-established and highly effective platform for targeted drug delivery, as their hollow core can encapsulate a wide variety of small-molecule drugs. The antibody is typically conjugated to the liposome surface via a polyethylene glycol (PEG) linker. This conjugation not only facilitates specific targeting but also improves the liposome's circulation time in the bloodstream by preventing rapid clearance by the reticuloendothelial system. The choice of antibody (whole antibody or fragments) and the conjugation strategy are critical to ensure the immunoliposome retains high binding affinity and stability, thereby maximizing its therapeutic potential. We utilize advanced techniques to ensure the antibody is correctly oriented and remains active, providing you with a reliable and powerful drug delivery solution.

Fig.3 The generation of dual-targeted immunoliposomes applying a two-step post-insertion approach.^3,4

• Polymer-Antibody Conjugation: Antibodies can also be conjugated to polymeric nanoparticles, providing a robust and flexible platform for drug delivery. This method is particularly useful for achieving sustained release and for applications where a biodegradable carrier is desired.

Are you currently facing long drug development cycles or challenges in obtaining stable, effective, and targeted therapeutics? Our Antibody-Based Conjugation Services from Creative Biolabs help you accelerate drug discovery and improve therapeutic efficacy through advanced bioconjugation technologies. By precisely linking antibodies to cutting-edge delivery systems, we enable you to obtain highly specific and potent drug conjugates, unlocking new possibilities in disease treatment.

What We Can Offer?

Creative Biolabs is at the forefront of targeted drug delivery innovation, with a team of experts with over two decades of collective experience. We offer a versatile range of products and services designed to meet your specific research and development needs.

Workflow

Why Choose Us?

Opting for Creative Biolabs signifies collaborating with a specialized cohort committed to pioneering research and scientific preeminence. Our decades of experience and commitment to quality ensure that your projects are in the hands of seasoned experts.

Contact Our Experts Today

Application

The versatility of antibody-delivery system conjugates allows them to be applied across a broad spectrum of biomedical fields:

• Targeted Drug Delivery: This is the most common application, where an antibody directs the delivery system, loaded with a drug, specifically to a diseased cell type (e.g., tumor cells), maximizing the therapeutic effect while minimizing side effects.
• Gene and mRNA Therapy: Antibody-LNP conjugates are at the forefront of targeted gene delivery, ensuring that therapeutic nucleic acids are delivered to the correct cell types, which is essential for the efficacy and safety of gene-based medicines.
• Immuno-Oncology: By conjugating antibodies with immunomodulatory drugs or cytokines, these systems can be precisely delivered to activate immune cells at a tumor site, enhancing the body's natural anti-cancer response.
• Diagnostics and Imaging: Antibody conjugates can carry imaging agents to specific biomarkers, enabling high-resolution visualization and early-stage detection of diseases such as cancer.
• Cellular Engineering: In research, these conjugates are used to manipulate cell behavior or to deliver specific molecules into cells with high precision.

Contact Us About Bioconjugation Services

Published Data

Fig.1 Employment of lipid-based vesicles functioning as transport vehicles for macamide 3-MBL.^1,4

A research methodology augmenting the clinical efficacy of Macamide N-3-Methoxybenzyl-Linoleamide (3-MBL), a candidate anticonvulsant agent. The research team optimized 3-MBL's potential by encapsulating it in PEGylated liposomes that were conjugated with OX26 F(ab')₂ antibody fragments. This advanced immunoliposome system was specifically designed to overcome the challenge of delivering drugs across the blood-brain barrier (BBB) by targeting Transferrin Receptors (TfR). In vivo experiments, conducted using a pilocarpine-induced status epilepticus model, demonstrated that the immunoliposome formulation was significantly more effective at controlling epileptic seizures compared to the free drug at the same dosage. The results further showed that the anticonvulsant effect of the targeted immunoliposomes was comparable to that of carbamazepine, a widely used FDA-approved antiepileptic drug. The study concludes that this strategy provides a promising new method for effective brain-targeted delivery of therapeutic macamides, setting a new standard for anticonvulsant epilepsy treatment.

FAQs

Creative Biolabs offers an unparalleled partnership in the field of Antibody-Delivery System Conjugation Services. Our comprehensive solutions, from custom synthesis and conjugation to pre-clinical validation, are designed to accelerate your research and development, providing you with targeted, effective, and reliable tools. We are committed to helping you achieve your therapeutic and diagnostic goals with scientific excellence.

Connect with our experts for project-specific consultation and detailed insights.

References

1. Vera-López, Karin J et al. "Using Immunoliposomes as Carriers to Enhance the Therapeutic Effectiveness of Macamide N-3-Methoxybenzyl-Linoleamide." Neurology international vol. 17,3 38. 3 Mar. 2025, DOI:10.3390/neurolint17030038.
2. Kumari, Mamta et al. "Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics." Beilstein journal of nanotechnology vol. 14 912-926. 4 Sep. 2023, DOI:10.3762/bjnano.14.75.
3. Mack, Katharina, et al. "Dual targeting of tumor cells with bispecific single-chain Fv-immunoliposomes." Antibodies 1.2 (2012): 199-214. DOI: 10.3390/antib1020199.
4. Distributed under Open Access license CC BY 4.0, without modification.

Our services are For Research Use Only. We do not provide services to individuals.